Kindstar Globalgene Tech Inc (9960) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Kindstar Globalgene Tech Inc stock HK$0.83, price HK$0.87, that is 4.0% below the price, quality 47 out of 100. Rating: fairly valued. Calculated from audited financials with 8 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range HK$0.8570 – HK$8.17 · fair‑value band HK$0.6800 – HK$1.03 · the HK$0.8650 price screens above the HK$0.8300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Kindstar Globalgene Tech in your weekly email
Every Wednesday you see whether Kindstar Globalgene Tech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Kindstar Globalgene Technology, Inc., an investment holding company, provides clinical testing services in the People's Republic of China and Mainland China. It operates through nine segments: Hematology Testing.
Show moreShow less
Genetic Diseases and Rare Diseases, Infectious Diseases, Oncology, Neurology, Maternity-Related Diseases, Routine Testing, CROs and R&D Project, and Others. The company offers esoteric testing services for hematology, oncology, neuroscience and infectious diseases.
It also engages in product development and technical services; reagent development and sales; car-t treatment; and E-commerce services.
The company's research and development projects, including molecular biology detection, flow cytometry detection, cytogenetic detection, and pathological detection technologies. Kindstar Globalgene Technology, Inc. was founded in 2003 and is headquartered in Wuhan, the People's Republic of China.
Stock analysis
Kindstar Globalgene Tech Inc (9960) currently trades at HK$0.8650, while our model-based Fair Value estimate is HK$0.8300, so the stock looks roughly fairly valued today (gap 4.2%).
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of HK$1.23 per share, and 2 of the 8 models we run sit above the HK$0.8650 price.
Bear case: the Multiples group reads lowest at HK$0.6100, and 6 of the 8 models stay below the price. Data coverage for this calculation is low.
Scenario range: HK$0.6800 (bear) to HK$1.03 (bull), the price of HK$0.8650 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Kindstar Globalgene Tech Inc reported revenue of 934M CNY in FY2025 versus 931M CNY in FY2021, a compound +0.1%/yr. Reported net income was −58.7M CNY in FY2025.
Key figures
Market cap HK$862M (≈ $110M) Micro · P/S ratio 0.94 · Dividend yield 9.8% · Net margin −6.3% · Return on equity −1.5% · Return on assets (EBIT) −0.4% (5-year average) · Operating margin −9.6% · Revenue (TTM) 950M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −4%, 9960 screens cheaper than that median.
Fair Value models
BearHK$0.6800Fair Value HK$0.8300BullHK$1.03
Price HK$0.8650 · Downside -4.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.31/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+0.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.9%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
5.1% (2022) → −11.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
Compare Kindstar Globalgene Tech Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−4.0% · Above median
Profitability
Return on assets−1.6% · Below median
Net margin (12 months)−4.4% · Below median
Operating margin (12 months)−9.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)3.7% · Below median
Dividend yield (12 months)9.8% · Top 25%
Balance sheet
Debt / equity0.08× · Below median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Kindstar Globalgene Tech Inc (9960) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of HK$0.8300 versus a price of HK$0.8650, about 4% lower (fairly valued).
What is the fair value of 9960?
Our model-based fair value for Kindstar Globalgene Tech Inc is HK$0.8300 (as of Nov 8, 2026), built from audited fundamentals. The current price: HK$0.8650.
What is the quality score of 9960?
Kindstar Globalgene Tech Inc has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kindstar Globalgene Tech Inc (9960)?
Our model-based price target is the fair value of HK$0.8300 (as of Nov 8, 2026) from 8 valuation models. Cautious scenario HK$0.6800, optimistic scenario HK$1.03. It is a calculation from audited fundamentals, not an analyst target.
What is the Kindstar Globalgene Tech Inc stock forecast for 2026?
Our models put fair value at HK$0.8300, about 4% lower versus a price of HK$0.8650 (fairly valued). Cautious scenario HK$0.6800, optimistic scenario HK$1.03. The calculation is refreshed regularly with new filings.
What is the revenue of Kindstar Globalgene Tech Inc (9960)?
Kindstar Globalgene Tech Inc reported trailing-twelve-month revenue of about 950M CNY (latest available figure, as of Nov 8, 2026).
Does Kindstar Globalgene Tech Inc pay a dividend?
Kindstar Globalgene Tech Inc currently shows a dividend yield of 9.83% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Kindstar Globalgene Tech Inc (9960) and when is the ex-dividend date?
Kindstar Globalgene Tech Inc pays a dividend of HK$0.085 per share a year, a dividend yield of 9.8%. The last ex-dividend date was Jun 9, 2026. Free cash flow covers the dividend 1.94 times. Our assessment: Cash covered. The dividend is fully funded by free cash flow. The payout ratio on earnings is not available for this company.
What growth is priced into Kindstar Globalgene Tech Inc (9960)?
For today's price to be fair in a discounted-cash-flow model, Kindstar Globalgene Tech Inc would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.9 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 9960 use?
Our models discount Kindstar Globalgene Tech Inc at 12.0 %: a base by market capitalisation (micro), damped by beta 0.63, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Kindstar Globalgene Tech Inc that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has Kindstar Globalgene Tech Inc (9960) delivered so far?
Over the past 5 years revenue at Kindstar Globalgene Tech Inc grew +0.9 % a year. The price currently implies free-cash-flow growth of less than minus 40 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Kindstar Globalgene Tech Inc (9960) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Kindstar Globalgene Tech Inc (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Kindstar Globalgene Tech Inc (9960)?
The free-cash-flow yield on the price is 5.94 %: that much free cash flow Kindstar Globalgene Tech Inc produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Kindstar Globalgene Tech Inc (9960)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kindstar Globalgene Tech Inc it is HK$0.8300 per share (as of Nov 8, 2026), against a price of HK$0.8650. It is the blended result of 8 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Kindstar Globalgene Tech Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 9960 trades above its calculated fair value: price HK$0.8650, fair value HK$0.8300, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9960?
No. The price is what the market pays today (HK$0.8650); the fair value is what the company's own numbers justify (HK$0.8300). For Kindstar Globalgene Tech Inc the two are HK$0.0350 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kindstar Globalgene Tech Inc worth?
The market values Kindstar Globalgene Tech Inc at about HK$862M (market capitalisation, as of Nov 8, 2026). Per share that is HK$0.8650; our models calculate a fair value of HK$0.8300 per share.
What do the bullish and bearish scenarios say about 9960?
Our models span a range for Kindstar Globalgene Tech Inc: cautious scenario HK$0.6800, base HK$0.8300, optimistic HK$1.03 per share (as of Nov 8, 2026, price HK$0.8650). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Kindstar Globalgene Tech Inc (9960)?
Balance-sheet figures for Kindstar Globalgene Tech Inc (as of Nov 8, 2026): return on equity −1.5%, debt of 0.08 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 9960 from its 52-week high?
Kindstar Globalgene Tech Inc trades at HK$0.8650, about 26% below its 52-week high of HK$1.17 and at the low of HK$0.8650 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.8300 is for.
Which stocks are comparable to Kindstar Globalgene Tech Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kindstar Globalgene Tech Inc stock attractive at the current price?
The data as of Nov 8, 2026: price HK$0.8650, calculated fair value HK$0.8300 (−4%), Quality Score 47/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9960 calculated?
We run Kindstar Globalgene Tech Inc through 8 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of HK$0.8300 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Kindstar Globalgene Tech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kindstar Globalgene Tech Inc (9960)?
The closing price on Nov 6, 2026 was HK$0.8650. Our model-based fair value is HK$0.8300, about 4% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kindstar Globalgene Tech Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Kindstar Globalgene Tech Inc
How large is the market capitalisation of Kindstar Globalgene Tech Inc (9960)?
The market capitalisation of Kindstar Globalgene Tech Inc is HK$862M (≈ $110M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kindstar Globalgene Tech Inc (9960)?
The price-to-sales ratio of Kindstar Globalgene Tech Inc is 0.94 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Kindstar Globalgene Tech Inc (9960)?
The dividend yield of Kindstar Globalgene Tech Inc is 9.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Kindstar Globalgene Tech Inc (9960)?
The net margin of Kindstar Globalgene Tech Inc is −6.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kindstar Globalgene Tech Inc (9960)?
The return on equity (ROE) of Kindstar Globalgene Tech Inc is −1.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kindstar Globalgene Tech Inc (9960)?
On an EBIT basis the return on assets of Kindstar Globalgene Tech Inc is −0.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kindstar Globalgene Tech Inc (9960)?
The operating margin of Kindstar Globalgene Tech Inc is −9.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kindstar Globalgene Tech Inc (9960)?
Revenue at Kindstar Globalgene Tech Inc is growing +3.7% versus a year earlier (3y avg −12.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kindstar Globalgene Tech Inc (9960)?
Earnings per share at Kindstar Globalgene Tech Inc are growing −72.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Kindstar Globalgene Tech Inc (9960) carry?
The net debt of Kindstar Globalgene Tech Inc is 47.5M CNY (fiscal year 2025, ≈ 1.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Kindstar Globalgene Tech Inc in the live analysis
One click puts Kindstar Globalgene Tech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026